EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Şahin Bedir iD, Tanju Kapagan iD, Burçin Çakan Demirel iD, Merve Tokocin iD, Çiğdem Yıldırım, Semra Taş, Yakup Bozkaya, Abdilkerim Oyman, Nilufer Bulut iD, Gökmen Umut Erdem iD

Journal of Clinical Medicine · 02.03.2026 · 15 (5) · 1898

DOI: 10.3390/jcm15051898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.03.2026. Verfasst von Şahin Bedir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Istinye University, Gaziosmanpaşa Hospital, Istanbul 34250, Turkey. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognostic significance of low-level human epidermal growth factor receptor 2 (HER2) expression in hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer remains unclear, particularly in patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This study aimed to evaluate the impact of HER2-low status on treatment response and survival outcomes in this setting.

Methods

This multicenter retrospective cohort study included patients with HR+/HER2− metastatic breast cancer who received first-line endocrine therapy combined with palbociclib or ribociclib between January 2018 and May 2025. HER2-low tumors were defined as immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization, while HER2-zero tumors were classified as IHC 0. Treatment response, progression-free survival (PFS), and overall survival (OS) were compared between groups using Kaplan–Meier analysis and Cox regression models.

Results

A total of 309 patients were analyzed, including 122 (39.5%) with HER2-low disease and 187 (60.5%) with HER2-zero disease. Baseline clinicopathological characteristics were well balanced between groups. The overall response rate was 75.4% in the HER2-low group and 72.7% in the HER2-zero group (p > 0.05). Median PFS was 23.9 months for HER2-low patients and 25.2 months for HER2-zero patients (log-rank p = 0.785). Median OS was 49.5 and 53.1 months, respectively, with no statistically significant difference (log-rank p = 0.649). HER2 status was not an independent predictor of PFS or OS in multivariable analyses.

Conclusions

In patients with HR+/HER2− metastatic breast cancer treated with first-line endocrine therapy plus CDK4/6 inhibitors, HER2-low expression was not associated with differences in treatment response or survival outcomes. These findings suggest that HER2-low status does not have prognostic or predictive relevance in this endocrine-sensitive population.

Schlagwörter

Stichwörter der Autor:innen

CDK 4/6 inhibitorsHER2-lowHER2-zerobreast cancerendocrine therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Istinye University, Gaziosmanpaşa Hospital, Istanbul 34250, Turkey.
  • Department of Medical Oncology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul 34480, Turkey.
  • Department of Medical Oncology, Istanbul Medipol University, Medipol Mega University Hospital, Istanbul 34214, Turkey.
  • Department of General Surgery, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul 34100, Turkey.
  • Department of Medical Oncology, University of Health Sciences, Samatya Training and Research Hospital, Istanbul 34098, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Pamukkale University Hospital, Denizli 20360, Turkey.

ORCID-Profile: Şahin Bedir, Tanju Kapagan, Burçin Çakan Demirel, Merve Tokocin, Nilufer Bulut, Gökmen Umut Erdem

Zitieren

APA

Bedir, Ş., Kapagan, T., Çakan Demirel, B., Tokocin, M., Yıldırım, Ç., Taş, S., Bozkaya, Y., Oyman, A., Bulut, N., & Erdem, G. U. (2026). Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. Journal of Clinical Medicine, 15(5), 1898. https://doi.org/10.3390/jcm15051898

Vancouver

Bedir Ş, Kapagan T, Çakan Demirel B, Tokocin M, Yıldırım Ç, Taş S, et al. Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. Journal of Clinical Medicine. 2026;15(5):1898. doi:10.3390/jcm15051898

BibTeX
@article{Bedir2026,
  author = {Bedir, Şahin and Kapagan, Tanju and Çakan Demirel, Burçin and Tokocin, Merve and Yıldırım, Çiğdem and Taş, Semra and Bozkaya, Yakup and Oyman, Abdilkerim and Bulut, Nilufer and Erdem, Gökmen Umut},
  title = {Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {1898},
  doi = {10.3390/jcm15051898}
}
Kostenlos starten →